title: Bevacizumab treatment for choroidal neovascularization due to age-related macular degeneration in Japanese patients.
abstract: OBJECTIVE
  To assess intravitreal bevacizumab (IVB) for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in Japanese patients.
  
  
  METHODS
  Forty-seven patients treated with IVB for newly diagnosed subfoveal or juxtafoveal CNV (predominantly classic CNV, 15 eyes; minimally classic CNV, 11 eyes; occult CNV, 21 eyes) secondary to AMD and followed for more than 12 months were reviewed retrospectively. IVB (1 mg) was injected via the pars plana. Additional IVB or photodynamic therapy was administered for either persistent or recurrent exudation. The main outcome measurements were best-corrected visual acuity (BCVA), number of injections, and treatment other than bevacizumab.
  
  
  RESULTS
  The mean baseline visual acuity (VA) was 0.38 [logarithm of the minimum angle of resolution (logMAR), 0.42] and final VA was 0.42 (logMAR, 0.38). During 12 months, bevacizumab was injected a mean of 3.4 times. Eight eyes received additional treatment. Up until 12 months, the mean BCVA with predominantly classic CNV increased, whereas the BCVA with minimally classic or occult with no classic CNV stabilized. The mean number of injections for predominantly classic CNV was 2.5, that for minimally classic CNV was 4.9, and that for occult with no classic CNV was 3.3.
  
  
  CONCLUSIONS
  IVB was especially effective for predominantly classic CNV, but CNV with subretinal pigment epithelial lesions might recur or enlarge despite additional IVB.
authors.affiliation: Department of Ophthalmology, Osaka University Medical School, Yamadaoka, Suita, Japan.
authors.forename: Mihoko
authors.initials: M
authors.lastname: Suzuki
authors.forename: Fumi
authors.initials: F
authors.lastname: Gomi
authors.forename: Miki
authors.initials: M
authors.lastname: Sawa
authors.forename: Motokazu
authors.initials: M
authors.lastname: Tsujikawa
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Sakaguchi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D044466:Asian People / Q000208:ethnology; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000208:ethnology / Q000209:etiology; D004396:Coloring Agents; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007208:Indocyanine Green; D007267:Injections; D007564:Japan / Q000453:epidemiology; D008268:Macular Degeneration / Q000150:complications* / Q000208:ethnology; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D019233:Retreatment; D012189:Retrospective Studies; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004396:Coloring Agents; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D007208:Indocyanine Green
references.citation: Am J Ophthalmol. 2003 Dec;136(6):1049-61
references.pmid: 14644215
references.citation: Ophthalmology. 2008 Jan;115(1):141-6
references.pmid: 17582498
references.citation: Retina. 2005 Oct-Nov;25(7):815-27
references.pmid: 16205558
references.citation: Br J Ophthalmol. 1997 Feb;81(2):154-62
references.pmid: 9059252
references.citation: Am J Ophthalmol. 2007 Apr;143(4):566-83
references.pmid: 17386270
references.citation: Br J Ophthalmol. 2008 Jan;92(1):70-3
references.pmid: 17567661
references.citation: Hum Genet. 2006 Aug;120(1):139-43
references.pmid: 16710702
references.citation: Jpn J Ophthalmol. 2008 Mar-Apr;52(2):99-107
references.pmid: 18626732
references.citation: Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5
references.pmid: 16156152
references.citation: Retina. 2006 May-Jun;26(5):495-511
references.pmid: 16770255
references.citation: Eye (Lond). 2008 Jan;22(1):82-6
references.pmid: 17891059
references.citation: Am J Ophthalmol. 2008 Feb;145(2):249-256
references.pmid: 18067876
references.citation: Am J Ophthalmol. 2008 Feb;145(2):239-248
references.pmid: 18222192
references.citation: Acta Ophthalmol. 2008 Jun;86(4):372-6
references.pmid: 18028234
references.citation: N Engl J Med. 2006 Oct 5;355(14):1419-31
references.pmid: 17021318
references.citation: Arch Ophthalmol. 1984 Nov;102(11):1640-2
references.pmid: 6208888
references.citation: Br J Ophthalmol. 2008 Dec;92(12):1636-41
references.pmid: 18782803
references.citation: Endocr Rev. 1997 Feb;18(1):4-25
references.pmid: 9034784
references.citation: Am J Ophthalmol. 2007 Dec;144(6):850-857
references.pmid: 17949673
references.citation: N Engl J Med. 2004 Dec 30;351(27):2805-16
references.pmid: 15625332
references.citation: Retina. 2006 Apr;26(4):383-90
references.pmid: 16603955
references.citation: Retina. 2007 Apr-May;27(4):439-44
references.pmid: 17420695